Skip to content
Screener

Immix Biopharma, Inc. IMMX Q3 2025 earnings

Reported November 7, 2025 · Before market open

EPS-$0.24Miss by $0.05
EPS estimate-$0.19

Next report

Nov 6, 2026 (in 2 months)
EPS estimate-$0.18

Financials

Q3 2025

Income statement

See full
Operating income-$7.7M-3.6%
Net income-$7.6M-6.1%
EPS (diluted)-$0.240.0%

Balance sheet

See full
Cash & equivalents$15.9M-19.0%
Total debt$1.1M+1.6%
Total equity$8.3M-52.9%
Total assets$20.1M-20.1%

Cash flow

See full
Operating cash flow-$5.9M-46.3%
CapEx$372.5K+37.2%
Free cash flow-$6.3M-45.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$68.27M+55.7%
Enterprise value$53.43M+112%

Returns & leverage

See full
Return on equity-182.5%+229pp
Debt / equity0.1×+0.1×
Current ratio1.5×-1.9×

FAQ

When did Immix Biopharma, Inc. report Q3 2025 earnings?
Immix Biopharma, Inc. (IMMX) reported Q3 2025 earnings on November 7, 2025 before market open.
What were Immix Biopharma, Inc.'s Q3 2025 revenue and EPS?
Immix Biopharma, Inc. reported eps of $-0.24 for Q3 2025.
Did Immix Biopharma, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.19 by $0.05.
How did Immix Biopharma, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 0.0% from $-0.24.
Where can I find Immix Biopharma, Inc.'s Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001493152-25-021325) directly on SEC EDGAR. The filing index links above go to sec.gov.